Please contact your representative at Oppenheimer & Co to request a 1-on ... of the author and do not necessarily reflect those of Nasdaq, Inc. Sign up for our newsletter to get the latest on ...

Highlights,Institutional interest grows as firms like Oppenheimer & Co. Inc. and Atria Investments expand their holdings in ...

CINCINNATI--(BUSINESS WIRE)-- Chemed Corporation (NYSE:CHE) today announced that it will deliver a virtual presentation at the Oppenheimer ... reflect those of Nasdaq, Inc. Sign up for our ...

MongoDB (NASDAQ:MDB – Free Report) had its price target reduced by Oppenheimer from $400.00 to $330.00 in a research report ...

PHOENIX, AZ / ACCESS Newswire / February 20, 2025 / Crexendo®, Inc. (NASDAQ:CXDO), an award-winning ... today announced that management will attend the Oppenheimer 10th Annual Emerging Growth ...

Financial industry leaders gathered at Nasdaq's Market Structure Seminar on February 11 to explore emerging trends shaping the global markets, with artificial intelligence and regulatory evolution ...

Fintel reports that on February 24, 2025, Oppenheimer upgraded their outlook for BioMarin Pharmaceutical (WBAG:BMRN) from Perform to Outperform. There are 1,111 funds or institutions reporting ...

As of March 4, 2025, the average one-year price target for Abeona Therapeutics is $16.22/share. The forecasts range from a low of $9.60 to a high of $22.05. The average price target represents an ...

Fintel reports that on February 24, 2025, Oppenheimer upgraded their outlook for BioMarin Pharmaceutical (NasdaqGS:BMRN) from Perform to Outperform. As of February 19, 2025, the average one-year ...

Fintel reports that on February 11, 2025, Oppenheimer initiated coverage of International Business Machines (BRSE:IBM) with a Outperform recommendation. There are 4,119 funds or institutions ...

--(BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that Amylyx management will present at the virtual Oppenheimer 35th Annual ...